Thank you for downloading the SR-MKT-TcBuster-FAQ-Dec2022
The benefits of non-viral gene engineering, when compared with its viral counterpart, offer simplicity, and streamlined capabilities all while lowering risk and cost. TcBuster as part of the ScaleReady portfolio empowers cell therapy programs to move to market faster and with superior scalability ensuring confidence in reproducibility, bench to bedside.
Latest Insights
Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy
Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.
Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success
Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.
Advancing Immune Cell Therapies Through Efficient Cell Culture Techniques
In an expert roundtable discussion by Cell and Gene Therapy Insights, the potential of cell culture in immune cell therapies takes center stage, offering promising possibilities for the future of regenerative medicine.
Are you ready to scale?
Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.